Generations Genetics Labs

generations-labs.com

Generations Labs is the epitome of hereditary testing in Egypt for families. Generations Labs is a comprehensive lab that guides its patients through a process that gives them the best service for all genetic health needs. From pregnancy to DNA testing, we provide a wide range of services for both patients and physicians alike to fulfill all needs with the highest standards.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

CONFO THERAPEUTICS ENTERS COLLABORATIVE AGREEMENT WITH REGENERON

Confo Therapeutics | December 01, 2021

news image

Confo Therapeutics announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic antibody drug candidates. The agreement will leverage Confo’s expertise in addressing two GPCR targets for which func...

Read More

Business Insights, PHARMACY MARKET

XERIS PHARMACEUTICALS ANNOUNCES USFDA APPROVAL OF RECORLEV

Xeris Pharmaceuticals, Inc. | January 31, 2023

news image

On January 30, 2023, Xeris Biopharma Holdings, Inc., a leading biopharmaceutical company, announced that the Food and Drug Administration (FDA) granted orphan-drug exclusivity (ODE) to its subsidiary Xeris Pharmaceuticals, Inc. for Recorlev® (levoketoconazole) a cortisol synthesis inhibitor for the treatment of endogenous Cushing's syndrome in adult patients for whom surgery is not viable or has not been effective. levoketoconazole (Recorlev) being the first FDA-approved...

Read More

CPD AND LEARNING, VIEWS AND ANALYSIS

POSITIVE PHASE 2B TRIAL DATA: ZANIDATAMAB IN HER2-AMPLIFIED BILIARY TRACT CANCERS PRESENTED AT ASCO 2023 BY JAZZ PHARMACEUTICALS AND ZYMEWORKS

prnewswire | June 05, 2023

news image

Jazz Pharmaceuticals plc and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC). The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology. The abst...

Read More

Business Insights, PHARMA TECH

ELLIGO INTRODUCES AI-DRIVEN CLINICAL RESEARCH STUDY TECHNOLOGY TO EXPEDITE TRIALS

Elligo Health Research | January 25, 2023

news image

On January 24, 2023, Elligo Health Research®, the leading healthcare-enabling research organization, presented the DataAI Connect, a new data and technology platform that will facilitate data-driven, rapid clinical research. DataAI Connect, a scalable, end-to-end data platform, optimizes the clinical research workflow by decreasing human error and rapidly digesting patient data to speed up clinical studies. Elligo has created an industry-first AI-driven platform that sources...

Read More
news image

Pharma Tech

CONFO THERAPEUTICS ENTERS COLLABORATIVE AGREEMENT WITH REGENERON

Confo Therapeutics | December 01, 2021

Confo Therapeutics announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic antibody drug candidates. The agreement will leverage Confo’s expertise in addressing two GPCR targets for which func...

Read More
news image

Business Insights, PHARMACY MARKET

XERIS PHARMACEUTICALS ANNOUNCES USFDA APPROVAL OF RECORLEV

Xeris Pharmaceuticals, Inc. | January 31, 2023

On January 30, 2023, Xeris Biopharma Holdings, Inc., a leading biopharmaceutical company, announced that the Food and Drug Administration (FDA) granted orphan-drug exclusivity (ODE) to its subsidiary Xeris Pharmaceuticals, Inc. for Recorlev® (levoketoconazole) a cortisol synthesis inhibitor for the treatment of endogenous Cushing's syndrome in adult patients for whom surgery is not viable or has not been effective. levoketoconazole (Recorlev) being the first FDA-approved...

Read More
news image

CPD AND LEARNING, VIEWS AND ANALYSIS

POSITIVE PHASE 2B TRIAL DATA: ZANIDATAMAB IN HER2-AMPLIFIED BILIARY TRACT CANCERS PRESENTED AT ASCO 2023 BY JAZZ PHARMACEUTICALS AND ZYMEWORKS

prnewswire | June 05, 2023

Jazz Pharmaceuticals plc and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC). The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology. The abst...

Read More
news image

Business Insights, PHARMA TECH

ELLIGO INTRODUCES AI-DRIVEN CLINICAL RESEARCH STUDY TECHNOLOGY TO EXPEDITE TRIALS

Elligo Health Research | January 25, 2023

On January 24, 2023, Elligo Health Research®, the leading healthcare-enabling research organization, presented the DataAI Connect, a new data and technology platform that will facilitate data-driven, rapid clinical research. DataAI Connect, a scalable, end-to-end data platform, optimizes the clinical research workflow by decreasing human error and rapidly digesting patient data to speed up clinical studies. Elligo has created an industry-first AI-driven platform that sources...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us